A “biotech boom” is underway in the UK, according to a new report from UK investment management firm Downing.
World Health Organization (WHO) experts have called for central registry on human genome editing research is needed, among a committee consensus that it would be irresponsible for any scientist to conduct gene-editing studies in people.
The EU General Court yesterday, March 20, annulled a European Union Intellectual Property Office (EUIPO) decision and handed a trademark victory to Spain-based Prim.
Press releases in recent months that suggest the CRISPR IP saga is about to end are too optimistic and miss out many of the nuances of the current situation, according to Claire Irvine, partner at HGF.
Switzerland-based Novartis today, March 12, failed to convince the EU General Court that its ‘Smartsurface’ trademark should be registered for contact lenses.
Activist group No Patents on Seeds has filed an opposition against a patent on lettuce, owned by Dutch food supplier Rijk Zwaan Zaadteelt.
The EU General Court today, March 6, rejected an appeal against an European Union Intellectual Property Office decision to reject the registration of a mark formerly owned by Allergan.
The UK Competition and Markets Authority has provisionally found that pharmaceutical companies Auden Mckenzie and Waymade engaged in anti-competitive behaviour relating to hydrocortisone tablets.
The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.
Cambridge University has secured a partial trademark victory against Cambridge NeuroTech, a neuroscience biotech company, before the UK Intellectual Property Office.